Genomics England Adopts Illuminaa s BaseSpace Variant Interpreter for Cancer

Genomics England Adopts Illuminaa s BaseSpace Variant Interpreter for Cancer


In a little over a year since Illumina announced the Bioinformatics and Clinical Interpretation Partnership with Genomics England, the partnership has now set unified standards for data and analysis practices using BaseSpace Variant Interpreter software for tumor variant review. In the coming months, Genomics England will be expanding the use of BaseSpace Variant Interpreter for cancer to all NHS Genomic Medicine Centers, and Illumina will be removing the 'Beta' status from its software offering, and formally launching it for public release later this summer.



from Biotech News